Skip to main
XOMA

XOMA (XOMA) Stock Forecast & Price Target

XOMA (XOMA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

XOMA Royalty Corp is projected to experience significant revenue growth, with expectations of over 20% annual increases through 2026, largely driven by commercial sales for products such as Vabysmo and new launches like Ojemda and Miplyffa. The company's total income from royalty agreements surged to $28.5 million in 2024, a remarkable rise from $4.8 million in 2023, bolstered by higher revenues from purchased receivables and customer contracts. With forecasts indicating revenues of $49.0 million for 2026, alongside anticipated contributions from earlier-stage assets and milestone payments, XOMA's growth trajectory appears robust, supported by its strategic acquisitions and internal expansion.

Bears say

XOMA Royalty Corp has experienced revenue and net earnings variability due to fluctuations in the international market, which could be further exacerbated by economic downturns, new tariffs, or changes in governmental reimbursement policies. In addition, the company's dependency on unpredictable market conditions and the potential for failed clinical trials or insufficient funding raises concerns about its ability to progress drug development effectively. Furthermore, recent share price declines reflect a reaction to the removal of anticipated near-term revenue drivers, along with broader trends affecting the biotechnology sector, contributing to a negative outlook on the stock.

XOMA (XOMA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About XOMA (XOMA) Forecast

Analysts have given XOMA (XOMA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, XOMA (XOMA) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $63.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $63.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

XOMA (XOMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.